New Enterprise Associates 16, L.P.
New Enterprise Associates 16, L.P.'s purchase track record
New Enterprise Associates 16, L.P. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/23/2024 | MRKR | $1.77M | -62.6% | -58.5% | +0.9% |
| 4/11/2022 | TRVI | $5.00M | +31.3% | -36.0% | -18.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
Transaction History
| MRKR | ▲ Buy | Open Market | 554,250 | $1.8M | 12/23/2024 | View on chart |
| MIRM | ▼ Sell | Other | 2,000,000 | $0 | 6/13/2023 | View on chart |
| TRVI | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 | View on chart |
| TRVI | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Marker Therapeutics appears in Yahoo's October 16 top picks
Yahoo included Marker Therapeutics in its list of notable stocks for October 16. The mention may increase visibility among investors. The stock is currently near its $1.41 support level and has an RSI of 38.5, suggesting modest momentum.
Marker Therapeutics appears in Yahoo's October 16 top picks. Yahoo included Marker Therapeutics in its list of notable stocks for October 16. The mention may increase visibility among investors. The stock is currently near its $1.41 support level and has an RSI of 38.5, suggesting modest momentum.